Communique #47
1 July, 2021
WEEK IN REVIEW Updates to the Living Treatment Guideline New recommendations Three new recommendations for the use of Casirivimab plus imdevimab (REGEN-COV) The Disease-Modifying Treatment and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated the recent trial results from the RECOVERY Trial publication evaluating REGEN-COV (published 16 June) into the body of evidence for casivirimab plus imdevimab and made the following three recommendations:...